The Safety and Efficacy of Preoperative Immunotherapy Combined with Chemotherapy in Patients with Stage IIIA-IIIB Lung Squamous Cell Carcinoma

Ying Wang; Cheng He; Jiacong Liu; Simeng Wu; Xuhua Huang; Lichen Zhang; Wenbo Shu; Chen Gu; Yiqing Wang; Linhai Zhu; Jian Hu

doi:10.1055/s-0042-1758552

The Thoracic and Cardiovascular Surgeon, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Thorac Cardiovasc Surg 2023; 71(03): 222-230
DOI: 10.1055/s-0042-1758552

Original Thoracic

The Safety and Efficacy of Preoperative Immunotherapy Combined with Chemotherapy in Patients with Stage IIIA-IIIB Lung Squamous Cell Carcinoma

Autoren

Ying Wang‡^*

¹Operating Room Nursing Department, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
Cheng He‡^*

²Department of Thoracic Surgery, Zhejiang University School of Medicine, the First Affiliated Hospital, Hangzhou, China
Jiacong Liu‡^*

²Department of Thoracic Surgery, Zhejiang University School of Medicine, the First Affiliated Hospital, Hangzhou, China
Simeng Wu‡^*

³Department of Cardiothoracic Surgery, the Shaoxing Second Hospital, Shaoxing, China
Xuhua Huang

²Department of Thoracic Surgery, Zhejiang University School of Medicine, the First Affiliated Hospital, Hangzhou, China
Lichen Zhang

²Department of Thoracic Surgery, Zhejiang University School of Medicine, the First Affiliated Hospital, Hangzhou, China
Wenbo Shu

²Department of Thoracic Surgery, Zhejiang University School of Medicine, the First Affiliated Hospital, Hangzhou, China
Chen Gu

²Department of Thoracic Surgery, Zhejiang University School of Medicine, the First Affiliated Hospital, Hangzhou, China
Yiqing Wang

²Department of Thoracic Surgery, Zhejiang University School of Medicine, the First Affiliated Hospital, Hangzhou, China
Linhai Zhu

²Department of Thoracic Surgery, Zhejiang University School of Medicine, the First Affiliated Hospital, Hangzhou, China
Jian Hu

²Department of Thoracic Surgery, Zhejiang University School of Medicine, the First Affiliated Hospital, Hangzhou, China

Abstract

Alle Artikel dieser Rubrik

Abstract

Objective Data on preoperative immunotherapy combined with chemotherapy in potentially resectable lung squamous cell carcinoma (LUSC) remain scarce. This study was designed to investigate the safety and efficacy of preoperative immunotherapy and chemotherapy for stage IIIA-IIIB LUSC.

Methods This study consecutively enrolled stage IIIA-IIIB LUSC who received preoperative immunotherapy combined with chemotherapy between January 2019 and July 2021. Patients received two to four cycles of immunotherapy combined with platinum-based doublet chemotherapy (platinum + paclitaxel) before surgery. Patients were assessed radiographically every one to two cycles until surgery. Postoperative pathological evaluation was also performed. Follow-up was performed until at least 3 months after surgery.

Results Sixty-five patients with stage IIIA-IIIB LUSC were enrolled. The objective response rate was 78.46% (51/65), and no patients had progressive disease. Fifty-seven patients underwent surgery, and 55 patients achieved R0 resection. There were no perioperative deaths. The rate of pathological complete response (pCR) was 31.58% (18/57) and major pathological response was 68.42% (39/57). The incidence of grade 3 and 4 adverse reactions was 21.21 and 1.54%, respectively.

Conclusion Perioperative immunotherapy combined with chemotherapy followed by surgical resection for male patients with stage IIIA-IIIB LUSC was effective with a tolerable toxicity profile.

Keywords

lung squamous cell carcinoma - preoperative treatment - immunotherapy - chemotherapy - surgery

Volltext

Referenzen

References
1 Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022; 72 (01) 7-33
2 Yeh J, Marrone KA, Forde PM. Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer. J Thorac Dis 2018; 10 (Suppl. 03) S451-S459
3 Travis WD. Pathology of lung cancer. Clin Chest Med 2011; 32 (04) 669-692
4 Scagliotti GV, Parikh P, von Pawel J. et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26 (21) 3543-3551
5 Clements KM, Peltz G, Faries DE. et al. Does type of tumor histology impact survival among patients with stage IIIB/IV non-small cell lung cancer treated with first-line doublet chemotherapy?. Chemother Res Pract 2010; 2010: 524629
6 Planchard D, Popat S, Kerr K. et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29: iv192-iv237
7 Socinski MA, Obasaju C, Gandara D. et al. Current and emergent therapy options for advanced squamous cell lung cancer. J Thorac Oncol 2018; 13 (02) 165-183
8 Reck M, Rodríguez-Abreu D, Robinson AG. et al; KEYNOTE-024 Investigators. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375 (19) 1823-1833
9 Mok TSK, Wu YL, Kudaba I. et al; KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 2019; 393 (10183): 1819-1830
10 Herbst RS, Giaccone G, de Marinis F. et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med 2020; 383 (14) 1328-1339
11 Brahmer J, Reckamp KL, Baas P. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373 (02) 123-135
12 Gandhi L, Rodríguez-Abreu D, Gadgeel S. et al; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018; 378 (22) 2078-2092
13 West H, McCleod M, Hussein M. et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019; 20 (07) 924-937
14 Socinski MA, Jotte RM, Cappuzzo F. et al; IMpower150 Study Group. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 2018; 378 (24) 2288-2301
15 Paz-Ares L, Luft A, Vicente D. et al; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 2018; 379 (21) 2040-2051
16 Jotte R, Cappuzzo F, Vynnychenko I. et al. Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III Trial. J Thorac Oncol 2020; 15 (08) 1351-1360
17 Forde PM, Chaft JE, Smith KN. et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med 2018; 378 (21) 1976-1986
18 Shu CA, Gainor JF, Awad MM. et al. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 2020; 21 (06) 786-795
19 Provencio M, Nadal E, Insa A. et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 2020; 21 (11) 1413-1422
20 Shen D, Wang J, Wu J. et al. Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB-IIIB resectable lung squamous cell carcinoma. J Thorac Dis 2021; 13 (03) 1760-1768
21 Forde PM, Spicer J, Lu S. et al; CheckMate 816 Investigators. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med 2022; 386 (21) 1973-1985
22 Deng H, Liu J, Cai X. et al. Radical minimally invasive surgery after immuno-chemotherapy in initially-unresectable stage IIIB non-small cell lung cancer. Ann Surg 2022; 275 (03) e600-e602
23 Rice TW, Ishwaran H, Ferguson MK, Blackstone EH, Goldstraw P. Cancer of the esophagus and esophagogastric junction: an eighth edition staging primer. J Thorac Oncol 2017; 12: 36-42
24 Eisenhauer EA, Therasse P, Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45 (02) 228-247